Which HRT Works Best for Skin and Hair? A Provider-Guided Breakdown

The connection between declining estrogen and skin changes is well documented in clinical research; the evidence for hair is less consistent. Estrogen receptors appear in skin keratinocytes, fibroblasts, and the dermal papilla cells of hair follicles, so falling hormone levels affect multiple systems at once.

Cameron CR et al. (2024) describe HRT as the gold standard for vasomotor and vaginal symptoms of menopause, with well-known risks, including stroke, cardiovascular disease, breast cancer, and venous thromboembolism, that a provider weighs before prescribing. Skin and hair effects are a secondary consideration with a smaller evidence base, not a reason to start HRT on their own. The women's guide to hormone replacement therapy covers the broader clinical context.

Estrogen: collagen, moisture, and skin thickness

Estrogen activates fibroblast cells to synthesize collagen and stimulates hyaluronic acid production in the dermis. When estrogen falls, both processes slow. A review by Thornton MJ (2013) in Dermato-Endocrinology describes how estrogen deficiency after menopause leaves skin thinner, with less collagen, decreased elasticity, and increased dryness.

Sebum production also tends to decrease after menopause. Together, these changes can contribute to a weaker skin barrier, reduced moisture retention, and thinner, less resilient skin.

Progesterone: oil balance and scalp environment

The progestogen component in combined HRT is not neutral for skin and hair. Androgenicity differs significantly between natural micronized progesterone and some synthetic progestins. More androgenic progestins may stimulate sebum in ways that shift the scalp environment unfavorably. Natural micronized progesterone has little androgenic activity, so it is less likely to push sebum and the scalp environment in that direction.

Testosterone: a complex factor in women's hair

Testosterone's role in women's hair is less clear than estrogen's. Androgens may contribute to pattern thinning in susceptible women, and evidence that low testosterone causes hair thinning is limited, so testosterone is not a hair treatment. Sand J et al. (2023) in Clinics in Plastic Surgery note that the pathophysiology of hair loss is thought to differ between women and men, so sex factors into treatment decisions.

Testosterone is used off-label for women in the US, with no women-specific product. A provider assesses its relevance based on lab work, where sex hormone-binding globulin levels matter; the SHBG and testosterone guide covers what total testosterone values alone can miss.

Symptoms that may suggest low estrogen versus low testosterone in women:

• Dry, crepey skin and increased fine lines may suggest falling estrogen, which reduces collagen and hyaluronic acid production in the dermis.
• Diffuse scalp thinning may reflect falling estrogen, while a widening midline part may point to female pattern hair loss; telling them apart takes labs and a clinical exam.
• Reduced libido may point toward declining testosterone in perimenopausal women, though energy and muscle changes overlap with many other causes.
• Vaginal dryness, hot flashes, and disrupted sleep are more characteristic of low estrogen and less associated with low testosterone alone.

HRT delivery forms differ in how estrogen reaches tissue, and that difference matters for safety and may matter for skin and hair. The full taxonomy of HRT types and regimens is at how HRT formulations are structured and classified. A licensed provider determines the delivery method and dosing after labs.

A 2023 systematic review by Goldštajn MŠ et al. in Archives of Gynecology and Obstetrics compared transdermal and oral estrogen. The routes performed similarly on bone density, glucose, and lipids, and the clearest difference was a higher venous thromboembolism (VTE) risk with oral estrogen. Transdermal delivery also bypasses first-pass liver metabolism, but the review did not measure skin or hair, so route choice for those outcomes rests on mechanism rather than head-to-head data.

Whether HRT will help with hair loss depends on whether the underlying cause is estrogen decline. The proposed link between HRT and hair growth is that estrogen may help prolong the anagen, or active growth, phase of the hair cycle, though clinical evidence that HRT improves hair density is limited. Women whose thinning is tied to the hormonal shift of perimenopause or menopause may see a response when estrogen is replaced through provider-guided therapy. The best HRT for hair loss in a given case is a provider decision based on labs, and testosterone is not an established part of it, since androgens may contribute to pattern thinning in susceptible women.

Which type of hair loss responds to HRT and which does not

HRT may benefit diffuse thinning that tracks with the hormonal shift of perimenopause and menopause. It is not an established treatment for female pattern hair loss (androgenetic alopecia), the most common type of hair loss in women, which involves gradual shrinking of the follicle and has its own evidence-based options. Whether HRT will help with hair loss depends largely on matching the treatment to the correct diagnosis.

Van Zuuren EJ et al. (2016) in the Cochrane Database of Systematic Reviews found the clearest trial evidence in female pattern hair loss for topical minoxidil, while hormonal options such as spironolactone still need more trials. Shehan JN et al. (2023) in Facial Plastic Surgery review techniques that range from medications and injections to follicular unit extraction, all of which sit outside the scope of HRT.

For DHT-related hair loss and approaches including finasteride and minoxidil, the provider-led hair treatment page and the HRT and hair loss treatment guide cover those options in full.

Hair signals worth tracking while on HRT:

• Reduced daily hair shedding in the shower or on a brush may indicate that follicle cycling is stabilizing in response to improved estrogen levels.
• Thinning that keeps progressing at a widening part line may point to female pattern hair loss and is worth raising with a provider.
• Shedding that does not change after several months may mean the thinning has a cause other than estrogen decline.
• Shifting scalp oiliness or dryness may signal that the progestogen component is affecting the scalp environment and may warrant a provider review.

Research on HRT and skin outcomes points to possible gains in collagen content, moisture retention, and dermal thickness with estrogen therapy, but much of it comes from smaller studies with inconsistent results. Whether HRT helps skin broadly, and whether it helps with skin aging specifically, comes down to estrogen's role in these structural pathways. Thornton MJ (2013) reviews how estrogen acts on skin fibroblasts, keratinocytes, and sebaceous glands, while head-to-head data comparing HRT routes for skin outcomes remain limited.

For protocols pairing hormonal support with topical peptides and growth factors, the peptide and hormone skin health page and how hormones and peptides work together on skin cover complementary approaches.

What does HRT do to your face?

Estrogen receptors are present in facial skin, and their activation supports collagen synthesis and hydration. As estrogen levels fall, facial skin typically becomes drier, thinner, and less resilient. Any changes in skin texture, dryness, and firmness with treatment tend to be gradual, and effects vary by individual. A provider assesses whether facial changes have a hormonal origin through labs and a clinical exam.

Skin changes some women notice on HRT:

• Improved skin hydration and reduced dryness may reflect estrogen-driven hyaluronic acid support in the dermis.
• Changes in crepey skin texture, if any, may take longer to appear than hydration changes, because collagen turnover is slow.
• Some women may notice no visible skin change, which is one reason skin outcomes alone do not decide whether HRT is right.

Progestogen androgenicity is one variable that can distinguish combined HRT formulations in terms of skin and hair side effects. More androgenic progestins may contribute to acne or changes in facial hair in susceptible individuals. Not all progestogens behave the same way.

Possible side effects, uncommon at physiological doses, may include mild acne, increased facial hair, or scalp sensitivity if the protocol includes a progestogen with high androgenic activity. These effects may occur with certain synthetic progestins and are typically mild and reversible under provider monitoring.

Natural micronized progesterone, sometimes called bioidentical progesterone, lacks the androgenic activity of some synthetic progestins. Providers may prefer it when acne, oiliness, or scalp changes are a concern, although head-to-head skin and hair data are limited.

This is one reason two women on combined HRT at comparable estrogen levels may have different skin and hair responses. Progestogen selection is part of what makes the best HRT for skin and hair a provider-calibrated protocol, not a single product answer.

Skin changes, when they occur, tend to emerge gradually over months, because collagen turnover is slow. The skin does not change overnight. Hair cycle shifts may take longer, and visible changes in density, if they occur, can take several months or more to appear. Individual variation is wide.

A provider monitors response through quarterly provider check-ins rather than a fixed outcome schedule. Cameron CR et al. (2024) note that HRT prescribing involves ongoing decisions, such as cyclic versus continuous regimens and when to taper. Tracking the best HRT for skin and hair over time means revisiting the protocol as hormone levels shift across the menopausal transition.

The essential lab markers guide for hormone protocols covers what providers track at each check-in. If you are experiencing menopausal skin and hair changes, a conversation with a licensed clinician about your full symptom picture is the starting point before any protocol decision is made.

The short answer: skin and hair changes associated with estrogen decline may return gradually after discontinuation, because the underlying hormonal deficit returns. Direct data on skin and hair after stopping HRT are limited, so this expectation rests on mechanism rather than on trials that tracked women after discontinuation.

Dermal thickness and moisture changes may diminish over months. Hair cycling patterns may shift back toward the pre-treatment state as the anagen phase loses estrogen support.

The decision to stop must be made with a provider. Cameron CR et al. (2024) list tapering among the nuances of prescribing HRT, and that decision should reflect the full picture of menopausal symptoms, not skin or hair outcomes alone.